View ValuationCompumedics 将来の成長Future 基準チェック /56Compumedics利益と収益がそれぞれ年間43.5%と19.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に40.3% 43.6%なると予測されています。主要情報43.5%収益成長率43.58%EPS成長率Medical Equipment 収益成長14.6%収益成長率19.4%将来の株主資本利益率40.32%アナリストカバレッジLow最終更新日17 Apr 2026今後の成長に関する最新情報お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.お知らせ • Aug 18Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million.Price Target Changed • Dec 01Price target lowered to AU$1.00Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year.すべての更新を表示Recent updates分析記事 • Jan 29Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 26%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.お知らせ • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.分析記事 • Oct 16Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 29%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...お知らせ • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing分析記事 • Oct 07Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Oct 05Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 275% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, AustraliaNew Risk • Aug 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risk Market cap is less than US$100m (AU$54.7m market cap, or US$35.6m).Reported Earnings • Aug 28Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.分析記事 • Jul 28Even With A 25% Surge, Cautious Investors Are Not Rewarding Compumedics Limited's (ASX:CMP) Performance CompletelyCompumedics Limited ( ASX:CMP ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...分析記事 • May 27Does Compumedics (ASX:CMP) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Mar 30Compumedics Limited (ASX:CMP) Held Back By Insufficient Growth Even After Shares Climb 29%Compumedics Limited ( ASX:CMP ) shareholders have had their patience rewarded with a 29% share price jump in the last...New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$61.5m market cap, or US$38.7m).Reported Earnings • Mar 04First half 2025 earnings releasedFirst half 2025 results: Revenue: AU$47.1m (up 78% from 1H 2024). Net loss: AU$2.23m (down AU$2.37m from profit in 1H 2024).分析記事 • Feb 06Compumedics Limited's (ASX:CMP) Subdued P/S Might Signal An OpportunityWith a price-to-sales (or "P/S") ratio of 1x Compumedics Limited ( ASX:CMP ) may be sending very bullish signals at the...お知らせ • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct Listing分析記事 • Oct 24This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks AppropriateKey Insights Compumedics to hold its Annual General Meeting on 31st of October CEO David Burton's total compensation...Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Oct 01Compumedics Limited, Annual General Meeting, Oct 31, 2024Compumedics Limited, Annual General Meeting, Oct 31, 2024. Location: 30-40 flockhart street, abbotsford victoria 3067 AustraliaReported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).分析記事 • Jun 17Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% BounceCompumedics Limited ( ASX:CMP ) shareholders would be excited to see that the share price has had a great month...New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (AU$51.4m market cap, or US$34.2m).分析記事 • Mar 07Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...New Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risk Market cap is less than US$100m (AU$34.5m market cap, or US$22.5m).分析記事 • Nov 03We Think Compumedics (ASX:CMP) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.004 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 14% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.分析記事 • May 27Is Compumedics (ASX:CMP) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.分析記事 • Jan 25Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A CompanyIf we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? A business...お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Oct 19Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This YearThe disappointing performance at Compumedics Limited ( ASX:CMP ) will make some shareholders rather disheartened. At...分析記事 • Oct 14Compumedics (ASX:CMP) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Oct 01Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 29Compumedics Limited, Annual General Meeting, Oct 27, 2022Compumedics Limited, Annual General Meeting, Oct 27, 2022, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the company and the reports of the directors and the company's auditor for the year ended 30 June 2022; to consider the re-election of director; and to consider the adoption of remuneration report.Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 18Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million.分析記事 • May 02Is Compumedics (ASX:CMP) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022Compumedics Limited announced that Mr. Tucson Dunn, who was appointed a Director of the Company in May 2018, will retire as a Director of the Company, effective 31 March, 2022.Reported Earnings • Mar 03First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.分析記事 • Dec 08Compumedics (ASX:CMP) May Have Issues Allocating Its CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 27Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.分析記事 • Aug 09Compumedics (ASX:CMP) Will Want To Turn Around Its Return TrendsWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Jun 10Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • May 06Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Is New 90 Day High Low • Mar 09New 90-day low: AU$0.41The company is down 16% from its price of AU$0.49 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.分析記事 • Feb 25These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt ExtensivelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.007 (vs AU$0.001 in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$18.0m (down 1.4% from 1H 2020). Net income: AU$1.32m (up AU$1.16m from 1H 2020). Profit margin: 7.3% (up from 0.9% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 79% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.分析記事 • Dec 01How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?It is doubtless a positive to see that the Compumedics Limited (ASX:CMP) share price has gained some 32% in the last...Price Target Changed • Dec 01Price target lowered to AU$1.00Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year.お知らせ • Sep 07Compumedics Limited Announces Not to Provide Guidance for the Fiscal Year 2021Compumedics Limited announced that the ongoing and uncertain impacts of the COVID-19 Pandemic on key markets around the world make it very difficult to forecast the Company's expected results, for any given future period. As such, the Company remains unable to provide guidance at this time for the fiscal year 2021.お知らせ • Jul 17Compumedics Limited Announces That Sales Forecasts Will Remain Problematic Due to COVID-19 PandemicCompumedics Limited announced that initial sales pipelines for 2021 consistent with same time last year, with good new sales orders in the first weeks of 2021. Sales forecasts will remain problematic due to COVID-19 pandemic.業績と収益の成長予測ASX:CMP - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2028951381016/30/20278095816/30/202666424112/31/2025580-14N/A9/30/202555-1-42N/A6/30/202551-1-70N/A3/31/202549-1-70N/A12/31/202447-2-7-1N/A9/30/202449-1-40N/A6/30/2024500-12N/A3/31/2024500-12N/A12/31/2023501-12N/A9/30/202347-2-31N/A6/30/202343-6-40N/A3/31/202342-6-31N/A12/31/202241-6-22N/A9/30/202240-2-12N/A6/30/202239103N/A3/31/202237103N/A12/31/202134002N/A9/30/202135002N/A6/30/202136101N/A3/31/202135-212N/A12/31/202035-524N/A9/30/202035-514N/A6/30/202035-615N/A3/31/202038-105N/A12/31/2019413-15N/A9/30/2019414N/A5N/A6/30/2019424N/A5N/A3/31/2019413N/A4N/A12/31/2018403N/A3N/A9/30/2018383N/A2N/A6/30/2018373N/A1N/A3/31/2018362N/A0N/A12/31/2017342N/A-1N/A9/30/2017342N/A0N/A6/30/2017341N/A1N/A3/31/2017351N/A2N/A12/31/2016362N/A4N/A9/30/2016372N/A3N/A6/30/2016383N/A2N/A3/31/2016363N/A2N/A12/31/2015353N/A1N/A9/30/2015342N/A2N/A6/30/2015332N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CMPの予測収益成長率 (年間43.5% ) は 貯蓄率 ( 3.6% ) を上回っています。収益対市場: CMPの収益 ( 43.5% ) はAustralian市場 ( 11.9% ) よりも速いペースで成長すると予測されています。高成長収益: CMPの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: CMPの収益 ( 19.4% ) Australian市場 ( 6.2% ) よりも速いペースで成長すると予測されています。高い収益成長: CMPの収益 ( 19.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CMPの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 40.3 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 19:36終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Compumedics Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Ian MartinNew Street Research LLPPaul JenszPAC Partners Securities Pty. Ltd.Stephen ScottTaylor Collison Limited
お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
お知らせ • Aug 18Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million.
Price Target Changed • Dec 01Price target lowered to AU$1.00Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year.
分析記事 • Jan 29Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 26%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...
お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
お知らせ • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.
分析記事 • Oct 16Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 29%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...
お知らせ • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing
分析記事 • Oct 07Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Oct 05Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 275% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, Australia
New Risk • Aug 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risk Market cap is less than US$100m (AU$54.7m market cap, or US$35.6m).
Reported Earnings • Aug 28Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
分析記事 • Jul 28Even With A 25% Surge, Cautious Investors Are Not Rewarding Compumedics Limited's (ASX:CMP) Performance CompletelyCompumedics Limited ( ASX:CMP ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
分析記事 • May 27Does Compumedics (ASX:CMP) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
分析記事 • Mar 30Compumedics Limited (ASX:CMP) Held Back By Insufficient Growth Even After Shares Climb 29%Compumedics Limited ( ASX:CMP ) shareholders have had their patience rewarded with a 29% share price jump in the last...
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$61.5m market cap, or US$38.7m).
Reported Earnings • Mar 04First half 2025 earnings releasedFirst half 2025 results: Revenue: AU$47.1m (up 78% from 1H 2024). Net loss: AU$2.23m (down AU$2.37m from profit in 1H 2024).
分析記事 • Feb 06Compumedics Limited's (ASX:CMP) Subdued P/S Might Signal An OpportunityWith a price-to-sales (or "P/S") ratio of 1x Compumedics Limited ( ASX:CMP ) may be sending very bullish signals at the...
お知らせ • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct Listing
分析記事 • Oct 24This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks AppropriateKey Insights Compumedics to hold its Annual General Meeting on 31st of October CEO David Burton's total compensation...
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 01Compumedics Limited, Annual General Meeting, Oct 31, 2024Compumedics Limited, Annual General Meeting, Oct 31, 2024. Location: 30-40 flockhart street, abbotsford victoria 3067 Australia
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).
分析記事 • Jun 17Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% BounceCompumedics Limited ( ASX:CMP ) shareholders would be excited to see that the share price has had a great month...
New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (AU$51.4m market cap, or US$34.2m).
分析記事 • Mar 07Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
New Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risk Market cap is less than US$100m (AU$34.5m market cap, or US$22.5m).
分析記事 • Nov 03We Think Compumedics (ASX:CMP) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.004 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 14% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
分析記事 • May 27Is Compumedics (ASX:CMP) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
分析記事 • Jan 25Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A CompanyIf we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? A business...
お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 19Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This YearThe disappointing performance at Compumedics Limited ( ASX:CMP ) will make some shareholders rather disheartened. At...
分析記事 • Oct 14Compumedics (ASX:CMP) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Oct 01Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 29Compumedics Limited, Annual General Meeting, Oct 27, 2022Compumedics Limited, Annual General Meeting, Oct 27, 2022, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the company and the reports of the directors and the company's auditor for the year ended 30 June 2022; to consider the re-election of director; and to consider the adoption of remuneration report.
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 18Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million.
分析記事 • May 02Is Compumedics (ASX:CMP) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022Compumedics Limited announced that Mr. Tucson Dunn, who was appointed a Director of the Company in May 2018, will retire as a Director of the Company, effective 31 March, 2022.
Reported Earnings • Mar 03First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
分析記事 • Dec 08Compumedics (ASX:CMP) May Have Issues Allocating Its CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 27Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 09Compumedics (ASX:CMP) Will Want To Turn Around Its Return TrendsWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
分析記事 • Jun 10Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • May 06Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Is New 90 Day High Low • Mar 09New 90-day low: AU$0.41The company is down 16% from its price of AU$0.49 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.
分析記事 • Feb 25These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt ExtensivelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.007 (vs AU$0.001 in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$18.0m (down 1.4% from 1H 2020). Net income: AU$1.32m (up AU$1.16m from 1H 2020). Profit margin: 7.3% (up from 0.9% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 79% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
分析記事 • Dec 01How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?It is doubtless a positive to see that the Compumedics Limited (ASX:CMP) share price has gained some 32% in the last...
Price Target Changed • Dec 01Price target lowered to AU$1.00Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year.
お知らせ • Sep 07Compumedics Limited Announces Not to Provide Guidance for the Fiscal Year 2021Compumedics Limited announced that the ongoing and uncertain impacts of the COVID-19 Pandemic on key markets around the world make it very difficult to forecast the Company's expected results, for any given future period. As such, the Company remains unable to provide guidance at this time for the fiscal year 2021.
お知らせ • Jul 17Compumedics Limited Announces That Sales Forecasts Will Remain Problematic Due to COVID-19 PandemicCompumedics Limited announced that initial sales pipelines for 2021 consistent with same time last year, with good new sales orders in the first weeks of 2021. Sales forecasts will remain problematic due to COVID-19 pandemic.